International gynecologic cancer society (IGCS) 2021 meeting report

Published:November 01, 2021DOI:
      The 2021 annual global meeting of the International Gynecologic Cancer Society (IGCS) was held between August 30 and September 2, 2021 as a fully virtual meeting. The meeting, initially planned as a “hybrid” meeting to be held in Rome, Italy, was transitioned to a fully virtual meeting due to concern for the safety of international delegates as a result of the COVD-19 global pandemic. The program committee, co-chaired by Drs. Ana Oaknin (Spain) and Matthew Powell (USA), assembled a robust program that included master sessions in cervix, ovary, uterine and vulvar cancer, tumor boards, oral and featured posters sessions. In addition, a surgical education track was available that included multiple surgical education courses, surgical films and debates on hot topics.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Coleman R.L.
        • et al.
        Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
        Lancet Oncol. 2021; 22: 609-619
        • Moore K.N.
        • et al.
        Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
        Ann. Oncol. 2021; 32: 757-765
        • Makker V.
        • et al.
        Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer.
        J. Clin. Oncol. 2020; 38: 2981-2992
        • Oaknin A.
        • et al.
        Clinical activity and safety of the anti–programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair–deficient endometrial cancer.
        JAMA Oncol. 2020; 6: 1766